Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy

被引:10
|
作者
DeBernardo, RL
Perkins, RB
Littell, RD
Krasner, CN
Duska, LR
机构
[1] Massachusetts Gen Hosp, Div Gynecol Oncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02114 USA
来源
OBSTETRICS AND GYNECOLOGY | 2005年 / 105卷 / 05期
关键词
D O I
10.1097/01.AOG.0000153026.61249.c7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To compare the efficacy of dalteparin, a low-molecular-weight heparin, to unfractionated heparin (UFH) in the prevention of deep venous thrombosis (DVT) and pulmonary embolism in patients after surgery for gynecologic malignancy. METHODS: The medical records of all patients undergoing major surgery on the Gynecologic Oncology Service at the Massachusetts General Hospital from July 2002 through April 2003 were reviewed. Patients with confirmed malignancy were included. Between July 1, 2002, and November 15, 2002, dalteparin (5,000 U subcutaneously each day) was used for postoperative prophylaxis for DVT and pulmonary embolus. After November 15, 2002, the method of prophylaxis was changed to UFH (5,000 U subcutaneously every 8 hours) exclusively. Patients were evaluated for DVT or pulmonary embolus based on clinical suspicion using computed tomographic angiography, ventilation and perfusion scan, or lower extremity doppler. RESULTS: A total of 214 patients were identified who met study criteria. Dalteparin was administered to 103 patients, and UFH was administered to 111. The rates of clinically significant DVT or pulmonary embolus in patients receiving dalteparin and UFH were 8.9% and 1.2%, respectively (P = .009). Major risk factors for DVT or pulmonary embolus, including age, obesity, duration of surgery, and type of malignancy, did not differ between groups. There were no significant differences in bleeding complications or transfusion requirements between groups. CONCLUSION: The low-molecular-weight heparin dalteparin dosed 5,000 U daily is inadequate postoperative prophylaxis in women undergoing surgery for gynecologic cancer. In addition, heparin administered every 8 hours was not associated with increased bleeding complications. The use of dalteparin at the doses used in this study should be questioned until a large randomized trial shows efficacy m these high-risk patients. (c) 2005 by The American College of Obstetricians and Gynecologists.
引用
收藏
页码:1006 / 1011
页数:6
相关论文
共 50 条
  • [21] Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo
    Norrby, Klas
    Nordenhem, Arvid
    APMIS, 2010, 118 (12) : 949 - 957
  • [22] Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties
    Vignoli, A
    Marchetti, M
    Balducci, D
    Barbui, T
    Falanga, A
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (02): : 207 - 214
  • [23] Pharmacokinetics of the low molecular weight heparin dalteparin in cats
    Mischke, Reinhard
    Schmitt, Judith
    Wolken, Sonja
    Boehm, Claudia
    Wolf, Petra
    Kietzmann, Manfred
    VETERINARY JOURNAL, 2012, 192 (03): : 299 - 303
  • [24] Low-molecular-weight heparin in women with repeated implantation failure
    Lodigiani, Corrado
    Di Micco, Pierpaolo
    Ferrazzi, Paola
    Libre, Luca
    Arfuso, Veronica
    Polatti, Franco
    Benigna, Michela
    Rossini, Roberta
    Morenghi, Emanuela
    Rota, Lidia
    Brenner, Benjamin
    Setti, Paolo Emanuele Levi
    WOMENS HEALTH, 2011, 7 (04) : 425 - 431
  • [25] Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy
    Pettilä, V
    Kaaja, R
    Leinonen, P
    Ekblad, U
    Kataja, M
    Ikkala, E
    THROMBOSIS RESEARCH, 1999, 96 (04) : 275 - 282
  • [26] Perioperative low-molecular-weight heparin
    Carter, S
    JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1996, 78B (01): : 167 - 167
  • [27] LOW-MOLECULAR-WEIGHT HEPARIN IN HEMODIALYSIS
    DEUBER, HJ
    SCHULZ, W
    KLINISCHE WOCHENSCHRIFT, 1987, 65 (20): : 992 - 992
  • [28] Uses of low-molecular-weight heparin
    Bounameaux, H
    Goldhaber, SZ
    BLOOD REVIEWS, 1995, 9 (04) : 213 - 219
  • [29] ERYTHROMELALGIA AND LOW-MOLECULAR-WEIGHT HEPARIN
    CONRI, CL
    AZOULAI, P
    CONSTANS, J
    SEBBAN, A
    LEMOUROUX, A
    MIDY, D
    BASTE, JC
    THERAPIE, 1994, 49 (06): : 518 - 519
  • [30] LOW-MOLECULAR-WEIGHT HEPARIN - REPLY
    HULL, RD
    RASKOB, GE
    PINEO, GF
    NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (11): : 818 - 818